[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634408":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":39,"collaborators":42,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":25,"studyType":60,"phases":61,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":74,"whyStopped":25,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":25},{"fullName":5,"class":6},"Laval University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Valsartan","EXPERIMENTAL","Valsartan 40 mg\u002Ftablet twice daily. . Titration up to 160 mg twice daily based on tolerance, blood pressure and renal function.",[13],"Drug: Valsartan",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo twice daily",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Valsartan 40 mg\u002Ftablet twice daily vs placebo. Titration up to 160 mg twice daily based on tolerance, blood pressure and renal function.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo that looks like valsartan (caps)",[15],[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Jonathan Beaudoin","CONTACT","1 (418) 656-8711","2943","jonathan.beaudoin@criucpq.ulaval.ca",{"name":37,"role":32,"phone":33,"phoneExt":38,"email":25},"Maude Jolicoeur","7225",{"type":40,"investigatorFullName":31,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","MD",[43,45],{"name":44,"class":6},"Fondation IUCPQ",{"name":5,"class":6},"100634408","phase-2-effects-of-valsartan-on-atrial-mitral-regurgitation-100634408",false,"NCT07539298","Effects of VALsartan On atRIAl Mitral Regurgitation","Effects of VALsartan On atRIAl Mitral Regurgitation: A Pilot Randomized Controlled Trial","VALORIA","Inclusion Criteria:\n\n1. No evidence of mitral organic disease\n2. At least moderate left atrial dilatation (left atrial volume index ≥34 mL\u002Fm²)\n3. Normal (≥ 50%) left ventricular ejection fraction and\n4. At least moderate MR grade by multiparametric assessment.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Indication for or ongoing treatment with ACEI\u002FARB\n3. History of hypotension\n4. Hypertension (\\>140\u002F90 mmHg) \\*\n5. Planned cardiac surgery (CABG or valve)\n6. Ongoing or planned pregnancy\n7. Chronic renal failure with eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2\n8. Neurocognitive disorder\n9. History of hyperkalemia\n10. Medication interacting with valsartan","ALL","18 Years","85 Years",{"count":58,"type":59},50,"ESTIMATED","INTERVENTIONAL",[62,63],"PHASE2","PHASE3","The goal of this clinical trial is to learn whether valsartan can slow the progression of atrial functional mitral regurgitation (AFMR) in adults with preserved left ventricular ejection fraction. The study will also evaluate the safety and tolerability of valsartan in this population.\n\nThe main questions it aims to answer are:\n\n* Does treatment with valsartan reduce the progression of atrial functional mitral regurgitation compared with placebo?\n* Does valsartan have favorable effects on mitral valve leaflet remodeling and related cardiac structure and function?\n* Is valsartan safe and well tolerated in patients with atrial functional mitral regurgitation who do not currently require angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?\n\nResearchers will compare valsartan to a placebo (a look-alike substance with no active drug) to see if valsartan reduces the progression of atrial functional mitral regurgitation and improves clinical and imaging outcomes.\n\nParticipants will:\n\n* Take valsartan or placebo twice daily for 12 months, with dose adjustments based on blood pressure, kidney function, and tolerance\n* Undergo 3D echocardiography at baseline, 6 months, and 12 months\n* Complete a 6-minute walk test at baseline and 12 months\n* Complete the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 6 months, and 12 months\n* Undergo 24-hour ambulatory blood pressure monitoring at 1 month\n* Have regular safety monitoring, including phone follow-up at 7 days, blood tests at 1 month, and blood pressure checks after dose adjustments",[66],"Atrial Functional Mitral Regurgitation",[68,69,70,71,72,73],"mitral regurgitation","Atrial functional mitral regurgitation","valsartan","placebo","mitral valve leaflets","randomized, double-blind, placebo-controlled clinical trial","NOT_YET_RECRUITING","2026-05-07",{"date":77,"type":78},"2026-05-12","ACTUAL",{"date":80,"type":59},"2026-05-01",{"date":82,"type":59},"2029-12-01",{"name":31,"class":6}]